Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Change in Acquisitions & Divestments: 2020-2024

Historic Change in Acquisitions & Divestments for BridgeBio Pharma (BBIO) over the last 5 years, with Dec 2024 value amounting to $95.0 million.

  • BridgeBio Pharma's Change in Acquisitions & Divestments fell 74.82% to $8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $131.0 million, marking a year-over-year decrease of 5.40%. This contributed to the annual value of $95.0 million for FY2024, which is 14.07% down from last year.
  • As of FY2024, BridgeBio Pharma's Change in Acquisitions & Divestments stood at $95.0 million, which was down 14.07% from $110.6 million recorded in FY2023.
  • In the past 5 years, BridgeBio Pharma's Change in Acquisitions & Divestments registered a high of $479.7 million during FY2022, and its lowest value of $95.0 million during FY2024.
  • In the last 3 years, BridgeBio Pharma's Change in Acquisitions & Divestments had a median value of $110.6 million in 2023 and averaged $228.4 million.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first soared by 52.61% in 2021, then slumped by 76.95% in 2023.
  • Over the past 5 years, BridgeBio Pharma's Change in Acquisitions & Divestments (Yearly) stood at $249.1 million in 2020, then surged by 52.61% to $380.2 million in 2021, then rose by 26.17% to $479.7 million in 2022, then tumbled by 76.95% to $110.6 million in 2023, then fell by 14.07% to $95.0 million in 2024.